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Book Review  
 
When Experiments Travel: Clinical Trials and the Global Search for 
Human Subjects  




Adriana Petryna’s second book, When Experiments Travel, is a timely addition to the 
understanding of offshore clinical trials. Employing an anthropological perspective 
the book explores the organisational settings that enable these trials, the complex 
networks of interests they maintain and in which they unfold, and the ethical and legal 
tensions present within these settings. Continuing the investigative strategies 
developed in her study on how Chernobyl’s exposed populations negotiate health care 
access (2002)2, Petryna’s new research explores the impact made by pharmaceutical 
trials in Eastern Europe and Latin America. Her argument relies on data collected 
through extensive fieldwork in Poland, Brazil and the United States.  
 
The author sets the scene for the examination of global drug trial development by 
looking at the ways in which clinical trial evidence is constituted and experimental 
subjects are identified. ‘Treatment saturation’, characterised by a shrinking pool of 
available human subjects in the West for the pharmaceutical industry, an increasing 
demand both for new markets and for human research subjects in general, are 
identified as factors in the offshoring of clinical trials. Petryna shows how in the last 
20 years the sites of research have shifted from academic to contract research 
organisations (CROs), which are typically subcontracted by pharmaceutical sponsors 
to collect the evidence required for drug approval by the FDA (Federal Drug Agency 
in the USA) or the EMEA (the European Agency for the Evaluation of Medical 
Products). Such CROs are competitive trans-national businesses that run trials not 
only for the pharmaceutical industry but also for bio-technological products and 
medical devices. Their projected growth is faster than that of the pharma industry.  
 
Responsible for locating research sites, patients, local experts and ethical review 
boards and on occasions for drawing up study design and performing analyses, the 
CROs may work with primary healthcare facilities such as hospitals and consortia of 
medical specialists. Some even have centralised institutional review boards to review 
protocols and subject recruitment to ensure the safety of trial volunteers. Alongside 
more permissive national legislative environments, factors such as population disease 
profiles, mortality rates, patient trial costs and potential for future marketing of the 
drug to be approved are essential in identifying new clinical trial sites. Petryna’s 
analysis illustrates how regulatory requirements, both in terms of patient safety and 
standardised scientific protocols, are made sense of by local actors in different ways.  
 
The offshoring of clinical trials equally needs to produce convincing scientific 
evidence for each drug’s adoption and various strategies are presented by clinical trial 
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experts in relation to the inclusion/exclusion criteria for the selection of patients and 
the ways in which these impact upon the collected evidence. Issues of competition, 
economic profit, risk, transparency and ethics are weighted individually and 
collectively through a constant comparison between different countries and locations 
to illuminate further aspects of the complex dynamics created by various interests, 
actors and agencies.  
 
Petryna develops the concept of “experimentality” defined as a “distinct modus 
operandi”, “decentralised and diffused” which supports the global drug market. Her 
analysis suggests that experiments are more than simple hypothesis-testing 
instruments, “they are operative environments that redistribute public health resources 
and occasion new and often tense medical and social fields”.  In this process “the line 
between what counts as experimentation and what counts as medical care is in flux”. 
Furthermore, the ethics of offshore clinical trials remain, despite strict scientific 
protocols (and occasional scandals), a malleable ”workable document”. One instance 
of such malleability is the “expedient experimentality” presented by public health 
crises in African countries, where international ethics codes can easily be overlooked 
in favour of immediate access to valuable, yet vulnerable subjects. In order to present 
experiments as ethically standardised, the complex ethics surrounding the clinical 
trials placebo is addressed by providing equivalent medication or the best local 
treatment available. As the research aims to keep costs low, clinical trial locations are 
chosen so that the best local treatment is hardly better than placebo, for instance, 
vitamin C. Other examples on the offshoring of clinical trials to Eastern Europe and 
Brazil depict poignantly ethical conundrums regarding what happens in the aftermath 
of the trials both to patients and to health care systems.    
 
Yet, the issue of whether such trials are a public good or exploitative mechanisms 
remains complex. Petryna shows how in different ailing healthcare systems the 
opportunity of clinical trials seems attractive both to clinicians and administrators, 
who have few resources but great entrepreneurial spirit. Moreover, these trials may 
offer a glimpse of hope to patients with little access to medication. At the same time, 
as the trials unfold, they become powerful marketing tools for specific drugs, 
instrumental in the reorganisation of healthcare priorities and in the production of a 
pharmaceuticalization of health care in specific regions of the world (i.e. an increasing 
dependency on particular, expensive, but not necessarily cost-effective drugs, often 
introduced through clinical trials). In Brazil, for instance, patient groups mobilise 
public opinion to lobby for treatment access from the state to drugs previously on 
trial. Such developments raise further questions from regulators, governments, 
researchers, other medical practitioners and patients themselves, regarding the 
continuity of treatment and control over the patients’ trial data - matters that are 
neither part of the initial clinical trial contract or of the consent form, but emerge in 
the aftermath of the trials. Furthermore, such clinical trials can also provide 
opportunities for clinicians not only to distribute trial drug resources to patients, but 
also to carry out further research for the benefit of such patients and in the interests of 
their own national healthcare systems. It is here, argues Petryna, that a critical 
assessment of the localised impact of the drug trial political economy is undertaken. 
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Combining scientific rigour with the need to inform public opinion and support 
government healthcare decisions, researchers continue to monitor the use of clinical 
trial drugs in order to expose the shortcomings of organisational cultures in securing 
the integrity of scientific research and patient safety.  
 
To conclude, Petryna’s argument provides a rich, detailed and compelling account of 
the many economic and political interests, complex moral issues and cultural settings 
of offshore clinical trials. The book will be of particular relevance to scholars in 
sociology, anthropology and health studies, interested in the dynamics of 
pharmaceutical markets and their impact on less developed countries, and the 
production of scientific and clinical evidence.   
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